Navigation Links
Nuvelo and ARCA biopharma Advance Toward Completion of Merger
Date:12/1/2008

SAN CARLOS, Calif. and BROOMFIELD, Colo., Dec. 1 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) and ARCA biopharma, Inc., a privately-held biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that a special meeting of Nuvelo's stockholders will take place on Wednesday, January 7 at 9 a.m. PT at Nuvelo's headquarters at 201 Industrial Road, San Carlos, CA, 94070. The purpose of the special meeting is, among other matters, to approve the actions necessary to consummate the merger between the two companies announced on September 25, 2008.

Under the terms of the merger agreement, ARCA will become a wholly owned subsidiary of Nuvelo. Nuvelo will issue new shares of its common stock to ARCA common and preferred stockholders and assume outstanding ARCA options and warrants. When the merger closes, ARCA equity holders are expected to own or have the right to acquire approximately 67 percent of the common stock of the combined company on a fully-diluted basis. Current Nuvelo stockholders are expected to own approximately 33 percent of the common stock of the combined company on a fully-diluted basis. The board of directors of the combined company is expected to have seven representatives from the current ARCA board, and three representatives from the current Nuvelo board. The chief executive officer of the combined company is expected to be Richard B. Brewer, the chief executive officer of ARCA. After the merger occurs, the name of the combined company is expected to be changed to ARCA biopharma, Inc.

At the special meeting, the Nuvelo stockholders will be asked to approve the issuance of Nuvelo common stock to ARCA equity holders, and to approve amendments to Nuvelo's amended and restated certificate of incorporation to effect a reverse
'/>"/>

SOURCE Nuvelo, Inc.; ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
2. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
3. Nuvelo Reports Second Quarter 2008 Financial Results
4. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
5. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
6. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
7. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
8. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
9. InCode BioPharmaceutics Appoints New President and CEO
10. Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
11. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... 1, 2015 Research ... the addition of the "Oxidative Stress ... Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The global ...
(Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
(Date:6/1/2015)...  The Val Skinner Foundation is partnering with Discovery ... high school students focused on cancer genetics. Skinner made ... Event (LPGA Pros in the Fight to Eradicate breast ... West Caldwell, N.J. Skinner ... than $500,000 on Monday, bringing the foundation,s 16-year total ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Global Bio-alcohols Market 2015-2019 2Val Skinner Foundation Announces Partnership With Discovery Education 2
... May 25, 2011 /PRNewswire/ -- Vermillion, ... today announced that the United States Patent and Trademark Office ... entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s Disease." ... as well as combinations that include these biomarkers. ...
... 2011 VIVUS, Inc. (NASDAQ: ... 3, placebo-controlled clinical trial of the investigational drug avanafil ... following a radical prostatectomy. The study (REVIVE-RP, TA-303) met ... erectile function as measured by the Sexual Encounter Profile ...
... 24, 2011 Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers ... supplement, biotechnology and pharmaceutical companies – today announced ... rule 5550(a)(2), which concerns minimum bid price listing ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 2VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 3VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 4VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients 5Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... levels of folate in their red blood cells were more ... a chemical off switch for genes, researchers report in the ... co-author Jean-Pierre Issa, M.D., professor in MD Anderson,s Department of ... of aging, such as heart disease. Methyl groups attach to ...
... 2010)A class of drugs thought to kill cancer cells may ... normal immune cells, resulting in reduced cancer growth and spreada ... evaluated in the future. Researchers at the University of ... fifth most common cancer in the United States. Bladder cancer ...
... release of an online tool that will help scientists ... a cell,s transcription machinery where to start reading in ... Promoter Database (MPromDb) integrates the genome sequencing data generated ... mouse genomics. MPromDb pinpoints known promoters and predicts where ...
Cached Biology News:High red blood cell folate levels linked to silenced tumor-suppressors 2High red blood cell folate levels linked to silenced tumor-suppressors 3Some cancer drugs may block cellular 'cross talk' but not kill cancer cells 2New annotated database sifts through mountains of sequencing data to find gene promoters 2New annotated database sifts through mountains of sequencing data to find gene promoters 3
... Factor XIII in both reduced and non-reduced ... XIII B-chain or human Factor XII. Factor XIII ... composed of two subunits. Factor XIII-A is the ... 160kDa. Factor XIII is present in plasma as ...
... Anti-Lipid Phosphate Phosphatase 2 ... buffered aqueous solution ... saline containing 0.08% sodium ... from the human LPP2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
... Anti-MAPKAPK-2, Phospho-Specific(Thr 222 ) ... NaCl, 10 mM sodium HEPES, ... pH 7.5. Recognizes the ~47 ... 2 (MAPKAPK-2) protein phosphorylated at ...
Biology Products: